OncoSec Added to the Russell Microcap® Index
OncoSec Added to the Russell Microcap® Index |
[25-June-2018] |
SAN DIEGO and PENNINGTON, N.J., June 25, 2018 /PRNewswire/ -- OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, announced today that it has been added to the Russell Microcap® Index, effective Friday, June 22, 2018, after market close. Russell US Indexes are widely used by investment managers and institutional investors as the basis for index funds and as benchmarks for active investment strategies. Approximately $9 trillion in assets are benchmarked against Russell US Indexes. Russell US Indexes are part of FTSE Russell, a leading global index provider. OncoSec's addition to this index will increase the Company's already growing visibility and presence with institutional investors and greater financial community. Annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of May 11, 2018, ranking them by total market capitalization. FTSE Russell determines membership for its Russell US Indexes primarily by objective, market-capitalization rankings and style attributes. About FTSE Russell OncoSec Medical Incorporated Cautionary Note Regarding Forward-Looking Statements Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on management's current preliminary expectations and are subject to risks and uncertainties, which may cause our results to differ materially and adversely from the statements contained herein. Potential risks and uncertainties that could cause actual results to differ from those predicted include, among others, the following: uncertainties inherent in pre-clinical studies and clinical trials, such as the ability to enroll patients in clinical trials and the risk of adverse events; unexpected new data, safety and technical issues; our ability to raise additional funding necessary to fund continued operations; and the other factors discussed in OncoSec's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events. KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. ImmunoPulse® is a registered trademark of OncoSec Medical Incorporated, San Diego, CA, USA. CONTACT Investor Relations: Media Relations:
View original content with multimedia:http://www.prnewswire.com/news-releases/oncosec-added-to-the-russell-microcap-index-300671310.html SOURCE OncoSec Medical Incorporated | ||
Company Codes: NASDAQ-SMALL:ONCS |
© 2018 PR Newswire. All Rights Reserved.
#content-news .main-news{color:#737373;font-size:14px;line-height:inherit;text-align:inherit}